Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society

被引:33
|
作者
Pedro-Botet, Juan [1 ]
Mostaza, Jose M. [2 ]
Pinto, Xavier [3 ,4 ]
Banegas, Jose R. [5 ]
机构
[1] Univ Autonoma Barcelona, Hosp del Mar, Barcelona, Spain
[2] Hosp Carlos III, Madrid, Spain
[3] Univ Barcelona, Hosp Univ Bellvitge, Barcelona, Spain
[4] CIBERobn ISCIII, Barcelona, Spain
[5] Univ Autonoma Madrid, Dept Med Prevent & Salud Publ, Madrid, Spain
来源
关键词
Epidemiology; Hypercholesterolemia; Cardiovascular prevention; Cardiovascular risk; Lipid units;
D O I
10.1016/j.arteri.2013.07.006
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: To evaluate low-density lipoprotein-cholesterol (LDLc) goal achievement among dyslipidemic patients treated in lipid and vascular risk units of the Spanish Society of Arteriosclerosis (SEA). The LDLc goal was based on the 2007 European guidelines for cardiovascular prevention. Design: Observational, longitudinal, retrospective, multicenter national study that included consecutive patients of both sexes over 18 years of age referred for dyslipidemia and cardiovascular risk. Information was collected from medical records corresponding to two visits in the lipid unit. Results: We included 1,828 patients from 43 lipid units. In the initial visit, 846 (46.3%) patients were on lipid lowering drug treatment. On the follow-up there was a significant increase in the use of cholesterol-lowering agents, except for a decrease in the use of nicotinic acid. 65.3% of patients with vascular disease and 50.4% with diabetes achieved an LDLc level < 100 mg/dL. Overall, 44.7% of patients achieved the LDLc goal and the predictors in the multivariate analysis were age, waist circumference, diabetes and the presence of vascular disease. Conclusion: Dyslipidemic patients referred to SEA lipid units have improved LDLc goal achievement after follow-up compared with data reported from previous studies in other health care settings. This improvement was associated with a substantial increase in the prescription of statins, both in monotherapy and combined with ezetimibe. There is still a wide room for improvement in the effectiveness of hypercholesterolemia treatment. (C) 2013 Elsevier Espana, S.L. y SEA. All rights reserved.
引用
收藏
页码:155 / 163
页数:9
相关论文
共 50 条
  • [1] Perspectives on low-density lipoprotein cholesterol goal achievement
    Catapano, Alberico L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (02) : 431 - 447
  • [2] Therapeutic modalities following low-density lipoprotein cholesterol goal attainment
    Miller, Michael
    FUTURE LIPIDOLOGY, 2006, 1 (02): : 131 - 133
  • [3] Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea
    Kim, Siin
    Han, Sola
    Rane, Pratik P.
    Qian, Yi
    Zhao, Zhongyun
    Suh, Hae Sun
    PLOS ONE, 2020, 15 (01):
  • [4] Achievement of Low-Density Lipoprotein Cholesterol Targets in CKD
    Massy, Ziad A.
    Ferrieres, Jean
    Bruckert, Eric
    Lange, Celine
    Liabeuf, Sophie
    Velkovski-Rouyer, Maja
    Stengel, Benedicte
    Ayav, Carole
    Combe, Christian
    Fouque, Denis
    Frimat, Luc
    Herpe, Yves-Edouard
    Laville, Maurice
    Massy, Ziad
    Legrand, Karine
    Metzger, Marie
    Speyer, Elodie
    Moulin, Bruno
    Lebrun, Gaetan
    Magnant, Eric
    Choukroun, Gabriel
    Bourdenx, Jean Philippe
    Essig, Marie
    Azar, Raymond
    Smati, Mustafa
    Jamali, Mohamed
    Klein, Alexandre
    Delahousse, Michel
    Martin, Severine
    Thervet, Eric
    Belenfant, Xavier
    Urena, Pablo
    Vela, Carlos
    Chauveau, Dominique
    Panescu, Viktor
    Glowacki, Francois
    Hoffmann, Maxime
    Hourmant, Maryvonne
    Besnier, Dominique
    Testa, Angelo
    Zaoui, Philippe
    Chazot, Charles
    Juillard, Laurent
    Burtey, Stephane
    Keller, Adrien
    Kamar, Nassim
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (11): : 1546 - 1554
  • [5] LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis
    Lahoz, Carlos
    Maria Mostaza, Jose
    Pinto, Xavier
    Jose de la Cruz, Juan
    Ramon Banegas, Jose
    Pedro-Botet, Juan
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2015, 27 (01): : 1 - 8
  • [6] Low low-density lipoprotein cholesterol and cancer risk
    Strandberg, Timo E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (01) : 91 - 92
  • [7] Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China
    Wang, Xing
    He, Yan
    Wang, Tao
    Li, Chunming
    Ma, Zihui
    Zhang, Heng
    Ma, Handong
    Zhao, Hongxin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020, 25 (04) : 307 - 315
  • [8] The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering
    Farukhi, Zareen
    Mora, Samia
    CIRCULATION, 2018, 137 (01) : 20 - 23
  • [9] Statins, low-density lipoprotein cholesterol, and risk of cancer
    Alsheikh-Ali, Alawi A.
    Trikalinos, Thomas A.
    Kent, David M.
    Karas, Richard H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (14) : 1141 - 1147
  • [10] Low-density lipoprotein cholesterol goal attainment in high-risk family medicine patients
    Griend, Joseph P. Vande
    Saseen, Joseph J.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2009, 3 (03) : 195 - 200